Paper41753671
Serum Uric Acid-Reducing Effect and Intestinal Mucosal Barrier-Repairing Function of Limosilactobacillus reuteri MBHC10138.
Cheng J and 3 others. Microorganisms, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Serum Uric Acid-Reducing Effect and Intestinal Mucosal Barrier-Repairing Function of Limosilactobacillus reuteri MBHC10138. Papers, record 41753671. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41753671
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Serum Uric Acid-Reducing Effect and Intestinal Mucosal Barrier-Repairing Function of Limosilactobacillus reuteri MBHC10138.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 510170040617 | This research was funded by the Start-up Fund for Scientific Research of High-level Talents of Wuyi University. | PubMed | ||
| No. RS-2023-00301938 | This research was also supported by the Global - Learning & Academic research institution for Master's·PhD students, and Postdocs (LAMP) Program of the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education | PubMed | ||
| No. RS-2025-02663016 | by the Basic Science Research Program through the NRF funded by the Ministry of Education (No. RS-2025-02663016). | PubMed | ||
| MBHC001 | This study was supported by R & D budget of MBHC Co. Ltd., Korea for development of functional probiotics and microbiome. | PubMed |
Source PubMed
References68
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38674582 | Limosilactobacillus reuteri HCS02-001 Attenuates Hyperuricemia through Gut Microbiota-Dependent Regulation of Uric Acid Biosynthesis and Excretion. | Microorganisms | 2024 | https://conductscience.org/library/papers/38674582 | PubMed |
| 2 | 19725932 | Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? | Arthritis Res Ther | 2009 | https://conductscience.org/library/papers/19725932 | PubMed |
| 3 | 35334930 | Lactobacillus reuteri CCFM8631 Alleviates Hypercholesterolaemia Caused by the Paigen Atherogenic Diet by Regulating the Gut Microbiota. | Nutrients | 2022 | https://conductscience.org/library/papers/35334930 | PubMed |
| 4 | 26852926 | Intestinal Microbiota Distinguish Gout Patients from Healthy Humans. | Sci Rep | 2016 | https://conductscience.org/library/papers/26852926 | PubMed |
| 5 | 26863122 | PROGNOSTIC VALUE OF PLASMA TIGHT-JUNCTION PROTEINS FOR SEPSIS IN EMERGENCY DEPARTMENT: AN OBSERVATIONAL STUDY. | Shock | 2016 | https://conductscience.org/library/papers/26863122 | PubMed |
| 6 | 30843748 | Molecular mechanistic insight into the anti-hyperuricemic effect of Eucommia ulmoides in mice and rats. | Pharm Biol | 2019 | https://conductscience.org/library/papers/30843748 | PubMed |
| 8 | 19565556 | Hyperuricemia and risk of stroke: a systematic review and meta-analysis. | Arthritis Rheum | 2009 | https://conductscience.org/library/papers/19565556 | PubMed |
| 9 | 18636784 | A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? | Drug Saf | 2008 | https://conductscience.org/library/papers/18636784 | PubMed |
| 10 | 19337060 | A prospective study of gout and cancer. | Eur J Cancer Prev | 2009 | https://conductscience.org/library/papers/19337060 | PubMed |
| 11 | 32452918 | The role of uric acid in inflammasome-mediated kidney injury. | Curr Opin Nephrol Hypertens | 2020 | https://conductscience.org/library/papers/32452918 | PubMed |
| 12 | 35438552 | Probiotic Characterization of Lactobacillus brevis MJM60390 and In Vivo Assessment of Its Antihyperuricemic Activity. | J Med Food | 2022 | https://conductscience.org/library/papers/35438552 | PubMed |
| 13 | 23981744 | HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region. | Int J Rheum Dis | 2013 | https://conductscience.org/library/papers/23981744 | PubMed |
| 14 | 39600720 | Lactobacillus paracasei 259 alleviates hyperuricemia in rats by decreasing uric acid and modulating the gut microbiota. | Front Nutr | 2024 | https://conductscience.org/library/papers/39600720 | PubMed |
| 15 | 15743917 | HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/15743917 | PubMed |
| 16 | 34478742 | The Tight Junction Protein ZO-1 Is Dispensable for Barrier Function but Critical for Effective Mucosal Repair. | Gastroenterology | 2021 | https://conductscience.org/library/papers/34478742 | PubMed |
| 17 | 28028921 | Oscillospira and related bacteria - From metagenomic species to metabolic features. | Environ Microbiol | 2017 | https://conductscience.org/library/papers/28028921 | PubMed |
| 18 | 32219059 | Verification with the utility of an established rapid assessment of brain safety for newly developed vaccines. | Lab Anim Res | 2019 | https://conductscience.org/library/papers/32219059 | PubMed |
| 19 | 31056705 | URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. | Rheumatology (Oxford) | 2019 | https://conductscience.org/library/papers/31056705 | PubMed |
| 20 | 33764849 | Limosilactobacillus fermentum JL-3 isolated from "Jiangshui" ameliorates hyperuricemia by degrading uric acid. | Gut Microbes | 2021 | https://conductscience.org/library/papers/33764849 | PubMed |
| 21 | 32271169 | Gut-derived uremic toxin handling in vivo requires OAT-mediated tubular secretion in chronic kidney disease. | JCI Insight | 2020 | https://conductscience.org/library/papers/32271169 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42650279 | Blue Honeysuckle Extract Ameliorates Hyperuricemia by Modulating Gut Microbiota and Improving Liver-Kidney-Gut Axis Function. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42650279 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| OCLN | 100506658 | PubTator's text mining | https://conductscience.org/library/genes/100506658 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41753671
GET https://conductscience.org/api/papers/v1/41753671/references?page=2